Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

ClinicalTrials.gov ID: NCT04452318

Public ClinicalTrials.gov record NCT04452318. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 1:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2

Study identification

NCT ID
NCT04452318
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
3,303 participants

Conditions and interventions

Conditions

Not listed

Interventions

Not listed

Eligibility (public fields only)

Age range
1 Day and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 12, 2020
Primary completion
Oct 3, 2021
Completion
Oct 3, 2021
Last update posted
May 14, 2023

2020 – 2021

United States locations

U.S. sites
42
U.S. states
5
U.S. cities
31
Facility City State ZIP Site status
Regeneron Study Site Mesa Arizona 85210
Regeneron Study Site Tucson Arizona 85712
Regeneron Study Site Tucson Arizona 85724
Regeneron Study Site La Mesa California 91942
Regeneron Study Site La Palma California 90623
Regeneron Study Site Long Beach California 90806
Regeneron Study Site Los Angeles California 90035
Regeneron Study Site Los Angeles California 90036
Regeneron Study Site Los Angeles California 90095
Regeneron Study Site Montclair California 91763
Regeneron Study Site Northridge California 91324
Regeneron Study Site Oxnard California 93030
Regeneron Study Site Sacramento California 95817
Regeneron Study Site Sacramento California 95821
Regeneron Study Site San Diego California 92108
Regeneron Study Site San Francisco California 94127
Regeneron Study Site Stanford California 94305
Regeneron Study Site Torrance California 90502
Regeneron Study Site Torrance California 90505
Regeneron Study Site Aurora Colorado 80045
Regeneron Study Site Colorado Springs Colorado 80907
Regeneron Study Site Washington D.C. District of Columbia 20005
Regeneron Study Site Boca Raton Florida 33487
Regeneron Study Site Clearwater Florida 33756
Regeneron Study Site DeLand Florida 32720
Regeneron Study Site Ft. Pierce Florida 34982
Regeneron Study Site Hialeah Florida 33010
Regeneron Study Site Jacksonville Florida 32216
Regeneron Study Site Lakeland Florida 33810
Regeneron Study Site Loxahatchee Groves Florida 33470
Regeneron Study Site Maitland Florida 32751
Regeneron Study Site Miami Florida 33012
Regeneron Study Site Miami Florida 33125
Regeneron Study Site Miami Florida 33126
Regeneron Study Site Miami Florida 33136
Regeneron Study Site Miami Florida 33144
Regeneron Study Site Miami Florida 33184
Regeneron Study Site Miami Florida 33186
Regeneron Study Site Orlando Florida 32803
Regeneron Study Site Sarasota Florida 34239
Regeneron Study Site Tampa Florida 33612
Regeneron Study Site West Palm Beach Florida 33407

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04452318, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 14, 2023 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04452318 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →